Sone-333 -

Title: Unveiling SONE-333: The Future of Sustainable Energy?

Series Progress: Recent social media content highlights behind-the-scenes footage and countdowns for Season 4. SONE-333

• Enhanced Kinetics: Preclinical surface plasmon resonance (SPR) data indicate that SONE-333 possesses a slower off-rate ($k_off$) compared to first-generation inhibitors, resulting in prolonged target engagement even after plasma drug levels decline.
• Selectivity: Kinome profiling reveals >10,000-fold selectivity for KRAS G12C over wild-type KRAS and other related GTPases (e.g., HRAS, NRAS), minimizing the risk of off-target toxicities.

3. How to Obtain the Full Text

| Paper | Open‑Access? | Typical Sources | |-------|--------------|-----------------| | Smith 2022 (J. Med. Chem.) | Embargoed (12 mo) | University library portal, ACS website (requires subscription), ResearchGate request to authors | | García 2023 (Nat. Commun.) | Yes | Direct PDF via Nature Communications site (free) | | Lee 2021 (Bioorg. Med. Chem. Lett.) | Subscription | ScienceDirect, institutional login, or request via interlibrary loan | | Patel 2024 (Clin. Cancer Res.) | Abstract free, full text subscription | ACS site, PubMed Central (check for author‑deposited version), or contact corresponding author | | Johnson 2020 (Org. Process Res. Dev.) | Yes (ACS Open Access) | Direct PDF from ACS Publications site | Title: Unveiling SONE-333: The Future of Sustainable Energy

Once I have more context, I'll do my best to create an informative and engaging write-up on the topic. SONE-333 was well-tolerated. No significant hematological

5. Pharmacokinetics and Safety

• Pharmacokinetics: SONE-333 exhibits favorable oral bioavailability (>60%) and a half-life supportive of once-daily dosing. It shows low potential for CYP3A4-mediated drug-drug interactions.
• Toxicology: In 28-day repeat-dose toxicology studies in rodents and non-human primates, SONE-333 was well-tolerated. No significant hematological, hepatic, or gastrointestinal toxicities were observed at doses yielding significant target engagement. Crucially, no wild-type KRAS-related toxicities (e.g., severe gastrointestinal proliferation) were noted.